Lupin Inks Deal With Sino Universal To Market COPD Drug In China

Lupin Ltd. on Monday said it had signed a licence and supply agreement with Sino Universal Pharmaceuticals for commercialising its Tiotropium dry powder inhaler, in 18 microgram strength, in China. The inhaler is used in the treatment of chronic obstructive pulmonary disease.

Under the agreement, Sino Universal will handle regulatory approvals in China, while Lupin will act as the marketing authorisation holder and will manufacture the product, the company said in a press release.

Lupin said the inhaler is effective in improving lung function and quality of life for people with respiratory illnesses. The partnership will help expand the company’s presence in China, where the burden of respiratory conditions is growing, by ensuring timely access to reliable and innovative treatment, it said.